Vicapsys Life Sciences, Inc. (VICP) intrinsic value & 10-year financials
Vicapsys Life Sciences, Inc. (VICP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.40
- Market cap
- $13.8M
- Revenue (FY2023)
- —
- ROIC (10-yr avg)
- -894.0%
- Free cash flow (FY2023)
- —
VICP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2023 | — | -$1.2M | -$0.03 | — | — | 61.6% |
| FY2022 | — | -$984.8K | -$0.03 | — | — | 183.7% |
| FY2021 | — | -$236.9K | — | — | — | 83.0% |
| FY2020 | $50.0K | -$765.8K | — | — | -1531.7% | 1040.9% |
| FY2019 | — | -$1.4M | — | — | — | -5839.2% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Vicapsys Life Sciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Vicapsys Life Sciences, Inc. has earned high returns on invested capital, averaging 19.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Vicapsys Life Sciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Vicapsys Life Sciences, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.